Form 4: Recursion Pharmaceuticals CFO Ben R. Taylor Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.
Summary
- On April 1, 2025, Recursion Pharmaceuticals' CFO, Ben R. Taylor, had 26,571 Class A Common Stock shares withheld by the issuer to cover tax obligations.
- The price per share for the transaction was $5.095.
- Following the transaction, Taylor directly owns 842,099 shares of Class A Common Stock.
- Taylor also holds multiple stock options with varying exercise prices and expiration dates.
- These options grant him the right to buy shares of Class A Common Stock.
- The options have different vesting schedules, generally vesting monthly or quarterly, contingent on continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and restricted stock units, are standard practice in the pharmaceutical industry to incentivize performance and align management interests with shareholder value.
- Vesting schedules and exercise prices for stock options are typically structured to reward long-term commitment and growth in company value, similar to practices at companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
- The reporting of these transactions via Form 4 is a standard regulatory requirement, ensuring transparency in insider trading activities, consistent with SEC regulations applicable to all publicly listed companies.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it primarily concerns the executive's tax obligations.
- The disclosure provides transparency to stakeholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 11/17/2021 | 25% of shares subject to one stock option award vest and become exercisable. |
| 04/03/2022 | 25% of shares subject to one stock option award vest and become exercisable. |
| 07/01/2022 | 25% of shares subject to one stock option award vest and become exercisable. |
| 01/02/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable. |
| 03/01/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable. |
| 04/01/2025 | Transaction date for the withholding of shares to cover tax obligations. |
| 04/03/2025 | Date of signature for the Form 4 filing. |
| 07/01/2031 | Expiration date for one of the stock option awards. |
| 04/02/2031 | Expiration date for one of the stock option awards. |
| 11/26/2030 | Expiration date for one of the stock option awards. |
| 12/18/2034 | Expiration date for one of the stock option awards. |
| 02/03/2035 | Expiration date for one of the stock option awards. |
Keywords
Form 4, Beneficial Ownership, RXRX, Recursion Pharmaceuticals, Ben R. Taylor, CFO, Stock Options, Tax Withholding, Class A Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.